IO Biotech Files 8-K for Bylaw Amendments and Exhibits
Ticker: IOBT · Form: 8-K · Filed: Dec 16, 2024 · CIK: 1865494
| Field | Detail |
|---|---|
| Company | Io Biotech, Inc. (IOBT) |
| Form Type | 8-K |
| Filed Date | Dec 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing, financials
TL;DR
IO Biotech filed an 8-K for corporate updates and financials.
AI Summary
IO Biotech, Inc. filed an 8-K on December 16, 2024, reporting events that occurred on December 13, 2024. The filing primarily concerns amendments to its articles of incorporation or bylaws and the submission of financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Copenhagen, Denmark.
Why It Matters
This filing indicates corporate governance updates and the submission of financial information, which are standard but necessary disclosures for publicly traded companies.
Risk Assessment
Risk Level: low — This is a routine filing for corporate updates and financial disclosures, not indicating any immediate operational or financial distress.
Key Numbers
- 001-41008 — SEC File Number (Identifies the company's filing with the SEC.)
- 87-0909276 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- IO Biotech, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Copenhagen, Denmark (location) — Principal executive offices
- December 13, 2024 (date) — Date of earliest event reported
- December 16, 2024 (date) — Filing date
FAQ
What specific amendments were made to IO Biotech's articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary text of the 8-K.
What financial statements and exhibits are included in this filing?
The filing states that financial statements and exhibits are included, but the specific content is not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on December 13, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark.
What is IO Biotech's SEC file number?
IO Biotech's SEC file number is 001-41008.
Filing Stats: 573 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2024-12-16 06:06:59
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share IOBT The Nasdaq Stock Mar
Filing Documents
- d896239d8k.htm (8-K) — 25KB
- d896239dex31.htm (EX-3.1) — 109KB
- 0001193125-24-278985.txt ( ) — 288KB
- iobt-20241213.xsd (EX-101.SCH) — 3KB
- iobt-20241213_lab.xml (EX-101.LAB) — 18KB
- iobt-20241213_pre.xml (EX-101.PRE) — 11KB
- d896239d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Amended and Restated Bylaws of IO Biotech, Inc., to be in effect on December 13, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IO BIOTECH, INC. Date: December 13, 2024 By: /s/ Mai-Britt Zocca Name: Mai-Britt Zocca, Ph.D. Title: Chief Executive Officer